Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. GCTK
GCTK logo

GCTK Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
1.430
Open
1.420
VWAP
1.40
Vol
28.93K
Mkt Cap
1.42M
Low
1.360
Amount
40.41K
EV/EBITDA(TTM)
--
Total Shares
1.01M
EV
-3.19M
EV/OCF(TTM)
--
P/S(TTM)
--
Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
Show More

Events Timeline

(ET)
2026-01-29
08:10:00
Glucotrack Secures Three Patents for Blood Glucose Monitoring
select
2025-12-30 (ET)
2025-12-30
08:10:00
Glucotrack Signs Securities Purchase Agreement for Approximately $4M
select
2025-08-06 (ET)
2025-08-06
08:38:59
GlucoTrack appoints David Hirsh as medical director, cardiology
select
2025-07-08 (ET)
2025-07-08
08:37:20
GlucoTrack announces repurchase of Series A warrants
select
2025-06-25 (ET)
2025-06-25
08:41:43
GlucoTrack announces study of CBGM met all primary endpoints
select
2025-06-12 (ET)
2025-06-12
09:11:54
GlucoTrack announces 1-for-60 reverse stock split
select
2025-05-28 (ET)
2025-05-28
08:35:49
GlucoTrack elects Carr-Brendel to board of directors
select

News

stocktwits
8.5
01-29stocktwits
Glucotrack Secures Three New Patents for CBGM Technology
  • Patent Approval: Glucotrack has secured three new patents from the U.S. Patent and Trademark Office, numbered US 12,453,494, US 12,458,257, and US 12,458,258, which cover critical technologies for its implantable continuous blood glucose monitoring platform, thereby enhancing the company's intellectual property portfolio.
  • Technology Protection: The new patents protect innovations in sensor chemistry, intravascular lead design, and low-power electronics, all of which are integral to Glucotrack's implantable system, ensuring a competitive edge in the market.
  • Positive Market Reaction: Following the patent announcement, Glucotrack's stock rose over 12% in Thursday's premarket trading, reflecting investor optimism regarding the company's future commercialization prospects, which could drive an increase in market value.
  • Accelerated Commercialization: With the acquisition of these new patents, Glucotrack's long-term implantable monitoring system is closer to commercialization, expected to generate new revenue streams and strengthen its position in the medical device market.
Newsfilter
8.5
2025-12-30Newsfilter
Glucotrack Secures $4 Million from Institutional Investor in Stock Purchase Agreement
  • Financing Agreement Reached: Glucotrack has entered into a securities purchase agreement with a single institutional investor to sell 1,033,591 shares of common stock and warrants for 2,067,182 shares, expected to generate approximately $4 million, enhancing the company's liquidity to support operations.
  • Warrant Details: The warrants have an exercise price of $3.87 per share and will not be exercisable until shareholder approval is obtained, which is expected to provide flexibility in the company's future capital structure and support its long-term growth strategy.
  • Planned Use of Funds: The company intends to use the net proceeds from this offering for working capital and general corporate purposes, aiming to enhance its R&D capabilities and market promotion to further drive the commercialization of its diabetes monitoring technology.
  • Compliance Statement: The securities transaction relies on an exemption under Section 4(a)(2) of the Securities Act of 1933, with unregistered securities restricted from sale in the U.S., ensuring the company operates within compliance frameworks during its fundraising activities.
Benzinga
2.0
2025-09-15Benzinga
Major Stocks Including New Mountain Finance, Texas Instruments, and Analog Devices Decline in Monday's Pre-Market Trading
  • U.S. Stock Futures: U.S. stock futures rose this morning, with the Dow futures increasing by over 50 points, while several stocks, including New Mountain Finance Corporation, experienced significant declines in pre-market trading.

  • Stock Movements: New Mountain Finance shares fell 4.4% after a downgrade by B of A Securities, while other stocks like Kindly MD and aTyr Pharma saw sharp declines of 37.1% and 19.7%, respectively, following previous gains.

Benzinga
8.5
2025-09-15Benzinga
Check-Cap Shares Surge 183%; Discover 20 Stocks Making Moves in Premarket Trading
  • Check-Cap Ltd Merger Announcement: Check-Cap Ltd's shares surged 183% in pre-market trading following the announcement of a definitive merger agreement with MBody AI, which Chairman David Lontini described as a strategic move into a high-growth industry.

  • Other Notable Pre-Market Movements: Several stocks experienced significant pre-market trading changes, including Helius Medical Technologies (up 163.2%), InnSuites Hospitality Trust (up 118%), and AtlasClear Holdings (up 69.5%), while ECD Automotive Design and Sidus Space saw declines of 27.2% and 26.3%, respectively.

Benzinga
4.5
2025-09-12Benzinga
Dow Drops 200 Points as US Consumer Sentiment Declines in September
  • U.S. Stock Market Performance: The Dow Jones index fell over 200 points, down 0.44%, while the NASDAQ rose 0.41% and the S&P 500 gained 0.01%. Utilities stocks increased by 0.5%, but materials stocks dropped by 0.6%.

  • Consumer Sentiment Decline: The University of Michigan consumer sentiment index decreased to 55.4 in September from 58 in August, falling short of market expectations.

  • Notable Stock Movements: Allied Gaming & Entertainment shares surged 113% after announcing a Bitcoin and Ethereum investment, while GlucoTrack, Inc. rose 80% following a stock purchase agreement. Conversely, Next Technology Holding Inc. shares plummeted 54% due to a reverse stock split.

  • Global Market Trends: European shares were mixed, with the eurozone's STOXX 600 slightly up, while Asian markets mostly closed higher, led by Japan's Nikkei 225 gaining 0.89%.

Benzinga
4.5
2025-09-12Benzinga
US Stocks Show Varied Performance; Adobe Reports Positive Q3 Earnings
  • U.S. Stock Market Performance: U.S. stocks showed mixed results, with the Dow Jones falling 0.16%, while the NASDAQ rose 0.08%. Utilities stocks increased by 0.3%, but materials stocks dropped by 0.4%.

  • Adobe's Strong Earnings: Adobe Inc. reported better-than-expected third-quarter earnings of $5.31 per share and raised its fiscal 2025 outlook, with quarterly revenue reaching $5.99 billion.

  • Notable Stock Movements: Allied Gaming & Entertainment shares surged 106% after announcing investments in Bitcoin and Ethereum, while Next Technology Holding shares plummeted 55% following a reverse stock split.

  • Global Market Trends: European shares were mixed, with the eurozone's STOXX 600 rising 0.2%, while Asian markets mostly closed higher, led by Japan's Nikkei 225 gaining 0.89%.

Valuation Metrics

The current forward P/E ratio for GlucoTrack Inc (GCTK.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess GlucoTrack Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

list of IPO from 2023
Intellectia · 1210 candidates
Region: USFloating Shares: <= 20,000,000
Ticker
Name
Market Cap$
top bottom
LGHL logo
LGHL
Lion Group Holding Ltd
623.70K
RAYA logo
RAYA
Erayak Power Solution Group Inc
684.91K
BDRX logo
BDRX
Biodexa Pharmaceuticals PLC
792.57K
ADTX logo
ADTX
Aditxt Inc
829.40K
BNRG logo
BNRG
Brenmiller Energy Ltd
859.02K
TRNR logo
TRNR
Interactive Strength Inc
865.12K
Low float stock screener
Intellectia · 1484 candidates
List Exchange: XNYS, XNAS, XASEFloating Shares: <= 20,000,000
Ticker
Name
Market Cap$
top bottom
LGHL logo
LGHL
Lion Group Holding Ltd
638.91K
LRHC logo
LRHC
La Rosa Holdings
711.55K
RAYA logo
RAYA
Erayak Power Solution Group Inc
831.04K
NIVF logo
NIVF
NewGenIvf Group Ltd
864.77K
QH logo
QH
Quhuo Ltd
948.08K
BDRX logo
BDRX
Biodexa Pharmaceuticals PLC
1.01M
which stocks at set up to make big moves
Intellectia · 82 candidates
Relative Vol: >= 1.50Beta: HighRiskWeekly Average Turnover: >= 1,000,000Week Price Change Pct: >= $5.00
Ticker
Name
Market Cap$
top bottom
GCTK logo
GCTK
GlucoTrack Inc
3.56M
TRUE logo
TRUE
TrueCar Inc
225.91M
NEOV logo
NEOV
NeoVolta Inc
191.06M
LXRX logo
LXRX
Lexicon Pharmaceuticals Inc
566.90M
LCII logo
LCII
LCI Industries
3.66B
ELBM logo
ELBM
Electra Battery Materials Corporation
97.40M
what penny stocks will go up this week
Intellectia · 41 candidates
Market Cap: <= 300.00MPrice: <= $5.00Relative Vol: >= 1.50Weekly Average Turnover: >= 1,000,000Week Price Change Pct: >= $0.00
Ticker
Name
Market Cap$
top bottom
BOXL logo
BOXL
Boxlight Corp
1.73M
PAPL logo
PAPL
Pineapple Financial Inc
1.90M
ADTX logo
ADTX
Aditxt Inc
2.59M
FRGT logo
FRGT
Freight Technologies Inc
2.66M
IMTE logo
IMTE
Integrated Media Technology Ltd
3.15M
VEEE logo
VEEE
Twin Vee PowerCats Co
3.51M
stocks for quick profit opportunity
Intellectia · 163 candidates
Relative Vol: >= 1.50Beta: HighRiskWeek Price Change Pct: >= $0.00
Ticker
Name
Market Cap$
top bottom
GCTK logo
GCTK
GlucoTrack Inc
3.56M
GORO logo
GORO
Gold Resource Corp
189.27M
TRUE logo
TRUE
TrueCar Inc
225.91M
ZENV logo
ZENV
Zenvia Inc
47.05M
SCYX logo
SCYX
SCYNEXIS Inc
28.05M
NEOV logo
NEOV
NeoVolta Inc
191.06M
low float, high relative volume
Intellectia · 245 candidates
Relative Vol: >= 2Shares Outstanding: <= 50,000,000
Ticker
Name
Market Cap$
top bottom
GITS logo
GITS
Global Interactive Technologies Inc
6.25M
PAVM logo
PAVM
PAVmed Inc
11.92M
NAMM logo
NAMM
Namib Minerals
121.31M
SLGB logo
SLGB
Smart Logistics Global Ltd
75.44M
FRGT logo
FRGT
Freight Technologies Inc
2.66M
LSTA logo
LSTA
Lisata Therapeutics Inc
35.55M
give me for short term buy
Intellectia · 72 candidates
Rsi Category: moderateRelative Vol: >= 1.50Beta: ModerateRisk, HighRiskWeekly Average Turnover: >= 1,000,000Week Price Change Pct: >= $5.00
Ticker
Name
Market Cap$
top bottom
BOXL logo
BOXL
Boxlight Corp
1.73M
GCTK logo
GCTK
GlucoTrack Inc
3.56M
PAPL logo
PAPL
Pineapple Financial Inc
1.90M
NATH logo
NATH
Nathan's Famous Inc
412.18M
TRUE logo
TRUE
TrueCar Inc
225.91M
ELBM logo
ELBM
Electra Battery Materials Corporation
97.40M
short term high profit invest
Intellectia · 94 candidates
Relative Vol: >= 1.50Beta: HighRiskWeekly Average Turnover: >= 1,000,000Pe Ttm: <= 20Week Price Change Pct: >= $0.00
Ticker
Name
Market Cap$
top bottom
GCTK logo
GCTK
GlucoTrack Inc
3.56M
GORO logo
GORO
Gold Resource Corp
189.27M
TRUE logo
TRUE
TrueCar Inc
225.91M
NEOV logo
NEOV
NeoVolta Inc
191.06M
LXRX logo
LXRX
Lexicon Pharmaceuticals Inc
566.90M
LCII logo
LCII
LCI Industries
3.66B
top 10 penny stocks to invest in today
Intellectia · 545 candidates
Price: <= $5.00Weekly Average Turnover: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
GITS logo
GITS
Global Interactive Technologies Inc
6.25M
NAMM logo
NAMM
Namib Minerals
121.31M
SLGB logo
SLGB
Smart Logistics Global Ltd
75.44M
FRGT logo
FRGT
Freight Technologies Inc
2.66M
LSTA logo
LSTA
Lisata Therapeutics Inc
35.55M
ROMA logo
ROMA
Roma Green Finance Ltd
143.55M
what should i day trade today
Intellectia · 135 candidates
Price Change Pct: >= $2.00Relative Vol: >= 1.50Beta: HighRiskWeekly Average Turnover: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
GCTK logo
GCTK
GlucoTrack Inc
3.56M
TRUE logo
TRUE
TrueCar Inc
225.91M
NEOV logo
NEOV
NeoVolta Inc
191.06M
LXRX logo
LXRX
Lexicon Pharmaceuticals Inc
566.90M
LCII logo
LCII
LCI Industries
3.66B
ELBM logo
ELBM
Electra Battery Materials Corporation
97.40M

Whales Holding GCTK

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is GlucoTrack Inc (GCTK) stock price today?

The current price of GCTK is 1.4 USD — it has decreased -2.37

What is GlucoTrack Inc (GCTK)'s business?

Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.

What is the price predicton of GCTK Stock?

Wall Street analysts forecast GCTK stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GCTK is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is GlucoTrack Inc (GCTK)'s revenue for the last quarter?

GlucoTrack Inc revenue for the last quarter amounts to 0.00 USD, decreased

What is GlucoTrack Inc (GCTK)'s earnings per share (EPS) for the last quarter?

GlucoTrack Inc. EPS for the last quarter amounts to -4.64 USD, decreased -99.57

How many employees does GlucoTrack Inc (GCTK). have?

GlucoTrack Inc (GCTK) has 11 emplpoyees as of March 11 2026.

What is GlucoTrack Inc (GCTK) market cap?

Today GCTK has the market capitalization of 1.42M USD.